Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2
| Autor: | Ursula Schmidt-Erfurth, G. Matt, Roman Dunavoelgyi, Stefan Sacu, Christopher Schütze, Christian Ahlers, Franz Prager, Christian Pruente |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty genetic structures Bevacizumab Anticorps monoclonal Visual Acuity Angiogenesis Inhibitors Antibodies Monoclonal Humanized medicine Humans Macula Lutea Telangiectasis Intravitreal bevacizumab Telangiectasia Aged Retrospective Studies Macular telangiectasia Anti vegf Vascular disease business.industry Antibodies Monoclonal nutritional and metabolic diseases Middle Aged medicine.disease eye diseases Surgery Ophthalmology Intravitreal Injections Retinal Telangiectasis Female sense organs medicine.symptom business Follow-Up Studies medicine.drug Month follow up |
| Zdroj: | Eye. 24:1535-1542 |
| ISSN: | 1476-5454 0950-222X |
| DOI: | 10.1038/eye.2010.113 |
| Popis: | The aim of this study is to evaluate the long-term efficacy of intravitreal bevacizumab (IVB) for eyes with non-proliferative idiopathic macular telangiectasia type 2 (IMT2) and acute vision loss.In this interventional case series, treatment-naive eyes of 13 consecutive patients with IMT2 were included. Eyes with a recent onset of visual loss were treated with 0.04 ml IVB (n=7). Fellow eyes and eyes of patients without disease progression served as control group (CG) (n=12). Follow-up examinations included ophthalmoscopy, best-corrected visual acuity (BCVA), optical coherence tomography, and fluorescein angiography (FA).Mean follow-up time was 32±5.7 months in the treatment group (TG) (n=7) vs 29±8.8 months in the CG (n=16). Mean BCVA increased from logMAR 0.47±0.32 at baseline to logMAR 0.33±0.31 (P=0.21) at the last visit in the TG and decreased from logMAR 0.25±0.39 to logMAR 0.30±0.40 in the CG (P=0.17). All patients in the TG showed stabilisation or improvement in vision in Snellen lines in contrast to the CG (χ(2)-test P=0.04). Patients received on average 2.3±1.3 IVB injections. Mean central millimetre thickness in TG and CG was 260±83 and 201±32 μm at baseline vs 237±69 and 199±29 μm at the last visit, respectively (P=0.23 and 0.77). FA revealed a significant decrease of the juxtafoveal staining size at month 3 (P= 0.004) and a slight reduction at the last visit (P= 0.11) in the TG.Despite an overall moderate effect of IVB treatment, individual patients experience a marked functional and morphological long-term benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|